Regeneron's Bone Disease Therapy Garetosmab Meets Primary Endpoint in Phase 3 Trial for FOP

Gelonghui September 17 | Regeneron Pharmaceuticals, Inc. stated that an experimental treatment for a rare hereditary disease affecting bone tissue has achieved the primary goal of a late-stage trial. The company said its drug garetosmab significantly reduced abnormal bone growth in patients with progressive fibrodysplasia ossificans. The company plans to submit the drug's application for market approval in the United States by the end of 2025.